Orfadin (Nitisinone) Patent Expiration, LOE Window & CMS Spending
Orfadin (Nitisinone) by Swedish Orphan Biovitrum Ab Publ: FDA Orange Book LOE 2033-02-28, 3 AB generics, $14.2M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Swedish Orphan Biovitrum Ab Publ |
| FDA Application & Pathway | N021232 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2033-02-28 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $14.2M |
| 2024 Medicare Part D Spend | $243K |
| 2024 Medicaid Spend | $14.0M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |